Business Wire

Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease  

Del

For media excluding US/Canada and UK

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180523005102/en/

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in patients living with COPD. VESUTO® and OTIVATO® data were presented during the American Thoracic Society meeting (ATS) and PHYSACTO® data was recently published in the American Journal of Respiratory and Critical Care Medicine.1,2,3

Activity-related breathlessness is a characteristic feature of COPD.5 It limits patients’ exercise tolerance and has an impact on their daily activities, which can lead to a downward spiral of exercise avoidance and physical decline.5,6 Decreased activity results in patients experiencing further breathlessness during even lower levels of physical activity, leading to further worsening of their condition, and increasing the risk of disability and death.7 The internationally-recognised GOLD 2018 Strategy recommends maintaining or increasing physical activity for all COPD patients, regardless of disease severity.4

“It is of paramount importance that people with COPD remain as active as possible to minimise the impact of the disease on their daily lives,” said Professor Thierry Troosters, Head of the Research Group for Cardiovascular and Respiratory Rehabilitation, University of Leuven, Belgium and principal investigator for the PHYSACTO® study. “The VESUTO®, OTIVATO®, and PHYSACTO® studies collectively show how tiotropium/olodaterol, a LAMA/LABA therapy, makes it easier for people with COPD to engage in physical activity by reducing symptoms and difficulty related to physical activity, thus improving their ability to exercise.”

“Breathlessness is one of the hardest symptoms I deal with, but I try to do something active every day,” said Simon Barson, who has been living with COPD for 10 years. “Even though I get myself extremely exhausted when I cycle or walk, I do it anyway because I know I’ll get my breath back. I always feel better when I have exercised than when I have not.”

Recently presented and published study data include:

  • The VESUTO® study examined the efficacy of tiotropium/olodaterol on lung hyperinflation, exercise capacity and physical activity compared with tiotropium alone, in Japanese patients.2 In VESUTO®, tiotropium/olodaterol therapy demonstrated a significant improvement in hyperinflation compared with tiotropium, and showed a potential enhancement of exercise capacity in COPD patients.2
  • The OTIVATO® study examined the effect of tiotropium/olodaterol versus tiotropium alone on breathlessness in patients with COPD during a 3-minute constant speed shuttle test, to assess exertional breathlessness during walking.1 In OTIVATO®, tiotropium/olodaterol significantly reduced the intensity of breathlessness during walking compared to tiotropium alone.1
  • The PHYSACTO® study assessed the effects of tiotropium/olodaterol alone or in combination with 8 weeks of exercise training on exercise capacity and levels of physical activity in patients with moderate-to-severe COPD.3,8 In PHYSACTO®, tiotropium/olodaterol with or without exercise training increased exercise capacity in people with moderate to severe COPD significantly compared to those receiving placebo.3,8 A 12-week self-management behaviour modification programme was included for all four groups to provide an optimal environment for translating improvements in exercise capacity into increases in daily activity.3,8

These new data build on results from the MORACTO® and TORRACTO® 1&2 studies, and together demonstrate that tiotropium/olodaterol significantly reduces lung hyperinflation, reduces breathlessness during exercise and improves exercise endurance time enabling greater physical activity in patients living with COPD.1,2,3,9,10 The OTIVATO® and PHYSACTO® trials are part of the large-scale TOviTO® Phase III clinical trial programme investigating the efficacy and safety of tiotropium/olodaterol Respimat® in COPD.11,12,13,14,15,16,17,18,19,20

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/spiolto-respimat-enables-greater-physical-activity

Contact information

Media contact:
Boehringer Ingelheim
Corporate Communications
Media + PR
Friederike Middeke
Email: Friederike.Middeke@boehringer-ingelheim.com
Phone: +49 (6132) 77-141575
Fax: +49 (6132) 77-6601
or
Email: press@boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet22.10.2018 17:15Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis and ankylosing spondylitis were both published in The Lancet. The publication of the Phase 2 EQUATOR data also coincides with a plenary session presentation at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting. “The results of the EQUATOR and TORTUGA studies demonstrate that filgotinib improved the signs and symptoms of patients with psoriatic arthritis whose disease had not responded to prior therapies and independently, for those with ankylosing spondylitis,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “These findings represent an important step forward in our efforts to improve outcomes for people livin

First Data Polska Deploys Inside Secure’s Mobile Payment Technology To Securely and Easily Connect to Mastercard and Visa22.10.2018 15:36Pressemelding

Regulatory News: Inside Secure (Paris:INSD) (Euronext Paris: INSD), at the heart of security solutions for mobile and connected devices, today announced that First Data Polska S.A., a division of the global leader in commerce-enabling technology, selected Inside Secure technology to enable secure and flexible connections to Mastercard and Visa. First Data Polska S.A. chose Inside Secure’s Mobile Payment Client to easily integrate their solution with the Visa Token Service (VTS) and Mastercard Digital Enablement Service (MDES) – today’s major tokenization services that convert sensitive data into unique tokens that allow mobile payments to be processed. “Security and reliability are continual requirements for our services,” said Jolanta Rycerz, Member of Management Board at First Data Polska S.A. “We see Inside Secure as a valuable technology provider that enables us to easily migrate to the latest mobile payment technology and security standards. Thanks to Inside Secure, our customers,

PMI Launches Search for Next President and CEO22.10.2018 14:00Pressemelding

Project Management Institute (PMI), the world’s leading professional membership organization for project managers, announced today that it has retained Heidrick & Struggles to help the organization find its next President and Chief Executive Officer (CEO). The dynamic leader shall oversee the implementation of a new strategic plan and guide the organization toward a future designed to help thousands of project professionals around the world accelerate their careers and make ideas a reality. Heidrick & Struggles is a premier provider of executive search, leadership assessment and development, organization and team effectiveness, and culture shaping services globally. PMI will conduct a comprehensive global review of both internal and external candidates for this key position. The selected candidate will embody PMI’s core values and possess the skillsets necessary to advance the organization’s key goals. PMI’s next President and CEO will help it execute a bold new multi-year initiative d

E2open to Acquire INTTRA, Adding the World’s Leading Ocean Shipping Network and Software Provider, Creating an Integrated Global Supply Chain and Logistics Operating Network22.10.2018 13:43Pressemelding

E2open, the one place in the cloud to run your supply chain, today announced the acquisition of INTTRA, the leading ocean shipping network, software and information provider. The combination of INTTRA’s ocean carrier and shipper network with E2open’s industry leading business network will create a unified global logistics and supply chain network. E2open and INTTRA will join efforts to strengthen the connections and streamline the information flow between manufacturers, suppliers, shipping service providers, ocean carriers and all the participants in global trade. E2open is the largest cloud-based provider of networked supply chain solutions, featuring a complete portfolio of applications that enable the world’s most complex supply chains to better plan, collaborate, and execute their end-to-end operations. More than 70,000 partner companies and 200,000 users, many of the biggest brands and manufacturers across a range of industries, use the E2open network and platform to orchestrate t

Patient-Data Platform Raremark Raises £3m to Enable Precision Medicine in Rare Disease22.10.2018 12:00Pressemelding

Raremark, the leading patient-data platform in rare disease, has raised £3m in funding from investors, led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and from existing major investor the Cass Entrepreneurship Fund. The funding will be used to develop Raremark’s patient-engagement and data-analysis technology, helping biopharmaceutical companies to identify, engage and learn from patients, accelerating the development of new treatments. Raremark’s platform is the foundation for building research networks of rare disease patients and their families. Raremark provides biopharmaceutical companies with access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development. The Raremark platform engages and retains patients, leveraging machine-learning technologies in novel ways. The approach is designed to raise health literacy and informed participation in medical research, to improve the quality of existing therapies and t

Celltrion Healthcare Hosts Forum with Patient Advocacy Groups to Provide Information on the Use of Biosimilars in Oncology22.10.2018 11:50Pressemelding

To coincide with the ESMO 2018 Congress in Munich, Germany, Celltrion Healthcare invited perspective from experts including a physician and pharmacist to provide information to patient advocacy groups on the history of biosimilars, how they are tested and approved, their cost saving benefit and the wealth of clinical evidence already available on their use in order to improve understanding of biosimilars. The introduction of biosimilars in the treatment of cancer has the potential to reduce pressure on healthcare budgets and increase access to other innovative treatments or more potent regimens. This is achieved by offering more cost-effective alternatives to the reference medicinal products and by increasing competition in the market. Breast cancer is the most common cancer in women worldwide and accounts for a quarter of all cancer diagnoses in women.1 For the benefits of biosimilar use to be realised in oncology, and in the treatment of breast cancer, barriers to their uptake need t